These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 29889811)

  • 1. Characteristics of Children With Invasive Pneumococcal Disease After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine in England and Wales, 2010-2016.
    Makwana A; Sheppard C; Borrow R; Fry N; Andrews NJ; Ladhani SN
    Pediatr Infect Dis J; 2018 Jul; 37(7):697-703. PubMed ID: 29889811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
    Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
    Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive pneumococcal disease due to 22F and 33F in England: A tail of two serotypes.
    Amin-Chowdhury Z; Groves N; Sheppard CL; Litt D; Fry NK; Andrews N; Ladhani SN
    Vaccine; 2021 Apr; 39(14):1997-2004. PubMed ID: 33715901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Invasive Pneumococcal Disease Caused by Emerging Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in England: A Prospective Observational Cohort Study, 2014-2018.
    Amin-Chowdhury Z; Collins S; Sheppard C; Litt D; Fry NK; Andrews N; Ladhani SN
    Clin Infect Dis; 2020 Nov; 71(8):e235-e243. PubMed ID: 31955196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales.
    Ladhani SN; Andrews NJ; Waight P; Borrow R; Slack MP; Miller E
    Clin Infect Dis; 2014 Feb; 58(4):517-25. PubMed ID: 24300040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive Pneumococcal Disease in UK Children <1 Year of Age in the Post-13-Valent Pneumococcal Conjugate Vaccine Era: What Are the Risks Now?
    Kent A; Makwana A; Sheppard CL; Collins S; Fry NK; Heath PT; Ramsay M; Ladhani SN
    Clin Infect Dis; 2019 Jun; 69(1):84-90. PubMed ID: 30281069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood Deaths Attributable to Invasive Pneumococcal Disease in England and Wales, 2006-2014.
    Oligbu G; Collins S; Sheppard CL; Fry NK; Slack M; Borrow R; Ladhani SN
    Clin Infect Dis; 2017 Jul; 65(2):308-314. PubMed ID: 28605414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study.
    Ladhani SN; Collins S; Djennad A; Sheppard CL; Borrow R; Fry NK; Andrews NJ; Miller E; Ramsay ME
    Lancet Infect Dis; 2018 Apr; 18(4):441-451. PubMed ID: 29395999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
    Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN
    Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of 13-Valent Pneumococcal Conjugate Vaccine on the Serotype Distribution and Antibiotic Resistance Profiles in Children With Invasive Pneumococcal Disease.
    Gaviria-Agudelo CL; Jordan-Villegas A; Garcia C; McCracken GH
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):253-259. PubMed ID: 26907814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.
    van Hoek AJ; Sheppard CL; Andrews NJ; Waight PA; Slack MP; Harrison TG; Ladhani SN; Miller E
    Vaccine; 2014 Jul; 32(34):4349-55. PubMed ID: 24657717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use.
    Yildirim I; Lapidot R; Shaik-Dasthagirisaheb YB; Hinderstein S; Lee H; Klevens M; Grant L; Arguedas Mohs AG; Cane A; Madoff L; Johnson H; Ivanof C; Burns M; Pelton S
    Pediatrics; 2024 Jan; 153(1):. PubMed ID: 38087952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
    Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.